Understanding how long not coding RNAS control gene expression in cancer

Long non -coded rnas (LNCRNA) are a type of RNA molecule that do not carry instructions to make proteins. Instead, they influence the way other genes are expressed. There are tens of thousands of LNCRNAS in the human body, many of which are active in specific tissues or diseases such as cancer. However, understanding exactly what they are doing was an important challenge.

Led by Baylor College of Medicine First Authors DRS. Hua-Shin Chiu and Sonal Somvanshi, researchers at Baylor, University of Ghent in Belgium, Tsinghua University in China and other collaborative institutions collaborated to better understand how LNCRNAS operates. Their findings have revealed that LNCRNAs seem to regulate gene expression in a coordinated manner it had not seen before. Their study is the story of the issue of this month Cell genomic.

Long -coded RNAs have been involved in many basic cellular processes, including cell growth and tissue. They can bind the areas of DNA to regulate gene transcription to RNA or regulate post-transcript events-the treatment of these RNAs by altering their stability, degradation and translation into proteins.

“Despite their abundance and their connection to specific diseases, only the functions of some LNCRNAS have been fully characterized,” said the leader of the corresponding author Dr. Pavel Sumazin, Associate Professor of Pediatrics and a member of the Jan Cancer Center and Dan in Baylor. He is also director of BioinFormatics Core Laboratory at Texas Children’s Hospital. “However, these studies have often been unable to provide mechanical knowledge to LNCRNA mode.”

The group started by developing a powerful new computing tool called Bighorn that uses mechanical learning to predict where LNCRNAs are bound to DNA and which genes they regulate. Unlike older methods based on strict sequence matching, Bighorn is looking for more flexible “tires” in DNA that best reflects how LNCRNAS behaves in live cells.

We tried Bighorn in data from more than 27,000 samples, including many types of cancer. We found that it has surpassed the previous tools in the prediction of LNCRNA-DNA interactions. ”

Dr. HUA-SHENG CHIU, Assistant Professor of Pediatrics-Oncology at Baylor Children’s Hospital and Texas

Interestingly, Bighorn has been accurately identified cases where a single LNCRNA regulates a gene in both transcriptional and post-post-compartment levels-a new phenomenon that researchers call the coordinated setting. “These lncrnas can act as molecular attendants who control the stability and translation of MRNas who have helped to transcribe, leading to strictly conjugated expression profiles.”

To show how strong this approach can be, the group focused on a lncrna called Zfas1. This molecule is often at high levels in cancer cells and is predicted by Bighorn to regulate many important genes.

“One of the main goals of Zfas1 is Dicer1A cancer gene that plays a central role in the production of microornas-microscopic molecules that help to perfect gene expression, “Sumazin said.” We found that this Zfas1 not only helps recover Dicer1 The gene but also protects its mRNA from degrading. This double action makes Dicer1 depends closely on the expression of Zfas1which acts as a selector to set Dicer1 The levels, which in turn affect the entire Microornas network in the cell. ”

“While focusing on an interaction, our findings suggested that LNCRNAS regulates genes into cancers to effectively regulate cancer programs,” Sumazin said. “In every type of cancer cell, hundreds of LNCRNAS seem to control hundreds of genes in this double way, creating tightly associated expression patterns that are particularly important in diseases such as cancer.”

Bighorn tool is available to the public (https://openrna.org/) and the authors hope that they will help scientists reveal the new roles of LNCRNA in everything, from growth to aging to cancer.

Other contributors to this project include Chung-Te Chang, Eric James de Bony de Lavergne, Zhaowen Wei, Chih-Hung Hsieh, Wim Trypsteen, Kathleen A. Scorsone, Ektaben Patel, Tien T. Tang, David B. Flint, Flint, Mohammad Javad Najaf, Hyun, Sarah, Sarah, Sarah, Sarah, Sarah, Sarah, Sarah, Sarah, Sarah, Mohammad Javad Naja E. Woodfield, Sanjeev A. Vasudevan, Andras Attilas Heczey, M. Waleed Gaber, Gabriel O. Sawakuchi, Ting-Wen Chen, Pieter Mestdagh and Xuerui Yang. Researchers are linked to one or more of the following institutions: Baylor College of Medicine, Texas Children’s Hospital, University of Ghent – Belgium, University of Tsinghua – China, National Yang Ming Chiao Tung University – Taiwan and University Center Center Center.

This project was supported by the Cprit RP180674, RP200504 and RP230120 awards. The European Union Research and Innovation Program, in accordance with the grant agreement 826121, National Institute of Cancer Awards R21CA223140 and R21CA286257; A special research scholarship from the University of Ghent (BOF21/PDO/007). and the National Foundation of Natural Sciences of the Grants of China W2411012 and 32330022. The advanced BCM cores are supported by NIH P01CA261669, P30CA125123, S10OD018033, S10OD023469, S10OD02525 P30EY002520.